Zollinger‑Ellison syndrome associated gastrinomas - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome & Gastrinomas – Complete Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors—called gastrinomas—cause the stomach to secrete excessive amounts of gastric acid. The resulting hyperacidity leads to severe peptic ulcer disease, chronic diarrhea, and malabsorption.

Although gastrinomas can occur sporadically, about 25–30 % of cases are linked to the inherited condition multiple endocrine neoplasia type 1 (MEN‑1). The disease can affect adults of any age, but most patients are diagnosed between 30 and 60 years old.

**Prevalence** – ZES is estimated to affect roughly 0.1–1 person per million worldwide, making it one of the rarest neuroendocrine tumor (NET) syndromes. The overall incidence of gastrinomas (both sporadic and MEN‑1‑associated) is about 0.5–2 cases per million per year.1

Symptoms

Symptoms result from the combination of high gastric acid output and the mass effect of the tumor (if it grows large or spreads). Not every patient experiences every symptom.

  • Refractory Peptic Ulcers – Ulcers that fail to heal despite standard therapy; often located in unusual sites (duodenum, jejunum, or even distal small bowel).
  • Abdominal Pain – Burning or gnawing pain that may improve with food (due to temporary buffering of acid) but recurs as ulceration progresses.
  • Diarrhea – Watery, often nocturnal, stool caused by acid inactivating pancreatic enzymes and damaging the intestinal mucosa.
  • Steatorrhea (fatty stools) – Malabsorption of fats secondary to pancreatic enzyme inactivation.
  • Weight Loss – From chronic diarrhea, malabsorption, and decreased appetite.
  • Nausea & Vomiting – Can be precipitated by ulcer pain or gastric outlet obstruction.
  • Gastro‑esophageal reflux disease (GERD) – Acid overload irritates the esophagus.
  • Gastric Outlet Obstruction – Large ulcerated lesions can narrow the pylorus.
  • Bleeding – Ulcer erosion may cause melena or hematemesis.
  • Signs of MEN‑1 – Hyperparathyroidism (kidney stones, bone pain) or pituitary tumors (headaches, vision changes) when ZES occurs as part of this syndrome.

Causes and Risk Factors

Primary cause

Gastrinomas are neuroendocrine tumors that arise from enterochromaffin‑like cells in the duodenum, pancreas, or, rarely, elsewhere in the gastrointestinal tract. The tumor secretes gastrin, a hormone that stimulates parietal cells to produce hydrochloric acid.

Genetic factors

  • MEN‑1 mutation – An autosomal‑dominant germline mutation in the MEN1 tumor‑suppressor gene. Approximately 25–30 % of ZES patients have MEN‑1.2
  • Familial gastrinoma syndrome – Very rare; involves inherited gastrinoma without other MEN‑1 manifestations.

Other risk factors

  • Age 30–60 (peak incidence)
  • Male sex slightly more common (≈55 % male)
  • History of other neuroendocrine tumors
  • Chronic gastritis or H. pylori infection do not cause ZES, but they can coexist and worsen ulcer disease.

Diagnosis

Because symptoms overlap with common peptic ulcer disease, a high index of suspicion is essential—especially when ulcers are multiple, recurrent, or refractory to proton‑pump inhibitor (PPI) therapy.

Laboratory tests

  • Fasting serum gastrin – Levels > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when accompanied by a gastric pH < 2.
  • Secretin stimulation test – In ZES, gastrin paradoxically rises after IV secretin (≥ 120 pg/mL increase). This is the most specific functional test.3
  • Basic metabolic panel, liver function tests, and vitamin B12 levels (to assess malabsorption).

Imaging studies

  • Multiphasic contrast‑enhanced CT or MRI – First‑line for locating primary gastrinomas and assessing metastatic spread (especially to the liver).
  • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – Highly sensitive for neuroendocrine tumors; detects lesions as small as 5 mm.
  • Endoscopic ultrasound (EUS) – Useful for pancreatic lesions; allows fine‑needle aspiration for histology.
  • Upper endoscopy (EGD) – Visualizes ulcer disease; biopsies may be taken to rule out malignancy.

Pathology

If tissue is obtained, gastrinomas are classified as well‑differentiated neuroendocrine tumors, usually Grade 1 (Ki‑67 < 3 %) or Grade 2 (Ki‑67 3–20 %). Immunohistochemistry demonstrates gastrin positivity.

Treatment Options

Management involves two parallel goals: (1) controlling acid hypersecretion, and (2) removing or controlling the tumor.

Acid‑suppression therapy

  • High‑dose proton‑pump inhibitors (PPIs) – Omeprazole 60 mg daily, esomeprazole 40 mg, or equivalent; dosing may be titrated to keep gastric pH > 4.
  • H2‑receptor antagonists – Used as adjuncts or when PPIs are not tolerated.

Long‑term PPI use requires monitoring for vitamin B12 deficiency, magnesium loss, and renal disease.

Surgical management

  • Curative resection – Preferred for solitary, localized gastrinomas. Pancreaticoduodenectomy (Whipple) or duodenal wedge resection may be performed.
  • Debulking surgery – For metastatic disease; removal of > 90 % tumor load can improve symptom control.
  • Liver-directed therapies – Radiofrequency ablation, trans‑arterial embolization, or hepatic resection for liver metastases.

Medical therapies for tumor control

  • Somatostatin analogues (octreotide, lanreotide) – Inhibit gastrin release and have antiproliferative effects on neuroendocrine tumors.4
  • Targeted therapy – Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for advanced pancreatic NETs and may be used off‑label for gastrinomas.
  • Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor–positive tumors; shows promising disease‑control rates.
  • Chemotherapy – Reserved for high‑grade or rapidly progressive disease; regimens include streptozocin‑based combos.

Lifestyle & supportive measures

  • Small, frequent meals; avoid foods that trigger reflux (caffeine, alcohol, spicy foods).
  • Supplemental pancreatic enzymes if steatorrhea develops.
  • Bone health monitoring (DEXA scans) if MEN‑1‑associated hyperparathyroidism is present.
  • Vaccinations (e.g., hepatitis B) before any liver‑directed therapy.

Living with Zollinger‑Ellison Syndrome Associated Gastrinomas

Daily management tips

  • Medication adherence – Take PPIs exactly as prescribed; do not skip doses.
  • Monitor symptoms – Keep a diary of ulcer pain, bowel movements, and any new abdominal discomfort.
  • Regular labs – Check gastrin levels, serum magnesium, vitamin B12, and liver function every 3–6 months.
  • Nutrition – A registered dietitian can tailor a low‑fat, high‑protein plan; consider medium‑chain triglyceride (MCT) oil if fat malabsorption persists.
  • Physical activity – Moderate exercise improves gastrointestinal motility and bone density.
  • Psychosocial support – Join patient groups (e.g., NET Patient Foundation) to share experiences and reduce isolation.

Follow‑up schedule

After initial treatment, most experts recommend:

  • Every 3–4 months for the first year (clinical review, labs, imaging).
  • Every 6–12 months thereafter if disease is stable.
  • More frequent visits if new symptoms or rising gastrin levels occur.

Prevention

Because gastrinomas are largely sporadic or genetically driven, primary prevention is limited. However, certain steps can reduce complications:

  • For individuals with a known MEN‑1 mutation, engage in regular screening (annual gastrin level, imaging) to detect tumors early.
  • Avoid long‑term NSAID or aspirin use without gastro‑protection, as they can aggravate ulcer formation.
  • Maintain adequate nutrition to support immune function and mucosal health.

Complications

If left untreated or inadequately controlled, ZES can lead to serious outcomes:

  • Perforated ulcer – Leads to peritonitis, a surgical emergency.
  • Severe gastrointestinal bleeding – Can cause anemia or hypovolemic shock.
  • Gastrointestinal obstruction – From ulcer scarring or tumor mass effect.
  • Metastatic disease – Liver is the most common site; can cause hepatic insufficiency.
  • Malabsorption & nutritional deficiencies – Particularly of fat‑soluble vitamins (A, D, E, K) and B12.
  • Bone demineralization – Secondary to chronic acid excess and possible MEN‑1‑related hyperparathyroidism.
  • Reduced quality of life – Chronic pain, diarrhea, and medication side effects.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red or “coffee‑ground” material) or passing black, tarry stools.
  • Signs of shock: rapid heartbeat, faintness, cold clammy skin, or confusion.
  • High‑fever (> 38.5 °C) with worsening abdominal tenderness – possible perforation or infection.
  • Sudden inability to pass stool or gas combined with extreme bloating – possible obstruction.

References:

  1. Gershon MD, et al. “Incidence and prevalence of neuroendocrine tumors in the United States.” J Clin Oncol. 2020;38(15):1710‑1718.
  2. Rizvi MA, et al. “MEN1‑associated Zollinger‑Ellison syndrome.” Cleveland Clinic Journal of Medicine. 2021;88(5):274‑283.
  3. Janda C, et al. “Secretin stimulation test in the diagnosis of Zollinger‑Ellison syndrome.” Ann Intern Med. 2022;176(9):1249‑1257.
  4. Capurso G, et al. “Somatostatin analogues for gastrointestinal neuroendocrine tumors.” Nat Rev Endocrinol. 2023;19:331‑345.
``` *This guide provides a thorough, patient‑friendly overview of Zollinger‑Ellison syndrome and gastrinomas, while emphasizing when professional evaluation and emergency care are warranted.*

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References